Juno Therapeutics, Inc. operates as a biopharmaceutical company, which focuses on re-engaging the body&#x27;s immune system to revolutionize the treatment of cancer. It platforms include chimeric antigen receptors and T-cell receptors. The chimeric antigen receptors technology directs T-cells to recognize cancer cells based on expression of specific cell surface proteins. The T-cell receptors technology provides the T-cells with a specific T-cell receptor that recognizes protein fragments derived from either intracellular or extracellular proteins. The company was founded by Hans E. Bishop, Lawrence Corey, Richard D. Klausner and Robert T. Nelsen on August 5, 2013 and is headquartered in Seattle, WA.
